Ammoxetine vs Duloxetine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: Serotonin/norepinephrine transporter · full Major Depressive Disorder pipeline
Ammoxetine
Developed by CSPC Pharmaceutical Group
NCT06827431 · Phase 3 · completed
This was a randomized, quadruple-masked Phase 3 trial with 770 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-07-27. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Reported efficacy
Change from baseline in Montgomery Asperger Depression Scale (MADRS) score at the end of treatment (week 8) (From baseline to Week 8): Primary endpoint, week-8 MADRS change: significantly better than placebo (P<0.0001) and numerically better than sertraline (2026-07-27). (met)
Result source: NCT06827431
Duloxetine · Cymbalta
Marketed by Eli Lilly
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ammoxetine | Duloxetine |
|---|---|---|
| MADRS, change (acute) | —Not posted · NCT06827431 | —Not posted · NCT00036309 |
| CGI-S, change (acute) | —Not posted · NCT06827431 | —Not posted · NCT00036309 |
| MADRS response | —Not posted · NCT06827431 | —Not posted · NCT00036309 |
| MADRS remission | —Not posted · NCT06827431 | —Not posted · NCT00036309 |
| Relapse (% of patients) | —Not posted · NCT06827431 | —Not posted · NCT00036309 |
MADRS, change (acute)
- Ammoxetine
- —Not posted · NCT06827431
- Duloxetine
- —Not posted · NCT00036309
CGI-S, change (acute)
- Ammoxetine
- —Not posted · NCT06827431
- Duloxetine
- —Not posted · NCT00036309
MADRS response
- Ammoxetine
- —Not posted · NCT06827431
- Duloxetine
- —Not posted · NCT00036309
MADRS remission
- Ammoxetine
- —Not posted · NCT06827431
- Duloxetine
- —Not posted · NCT00036309
Relapse (% of patients)
- Ammoxetine
- —Not posted · NCT06827431
- Duloxetine
- —Not posted · NCT00036309
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Duloxetine: registry results are on file for Major Depressive Disorder, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ammoxetine's landscape · Duloxetine's landscape